Twenty One Capital Borrow Rate Increases to 191.65%
Written by Emily J. Thompson, Senior Investment Analyst
Latest data shows the largest indicative borrow rate increases among liquid option names include: Twenty One Capital, Inc. (XXI) 191.65% +8.89, Stubhub Holdings, Inc. (STUB) 16.00% +0.45, Kindly MD Inc (NAKA) 1.06% +0.31, Direxion Daily S&P Bear (SPXS) 10.10% +0.21, Northern Dynasty (NAK) 1.19% +0.19, Merck (MRK) 0.41% +0.16, Photronics (PLAB) 0.56% +0.15, ATAI Life Sciences (ATAI) 1.27% +0.15, Esperion (ESPR) 0.74% +0.14, and Cambium Networks (CMBM) 105.36% +0.14.
Analyst Views on ATAI
Wall Street analysts forecast ATAI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ATAI is 13.13 USD with a low forecast of 10.00 USD and a high forecast of 16.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
9 Analyst Rating
9 Buy
0 Hold
0 Sell
Strong Buy
Current: 3.900
Low
10.00
Averages
13.13
High
16.00
Current: 3.900
Low
10.00
Averages
13.13
High
16.00
About ATAI
AtaiBeckley Inc. is a clinical-stage biotechnology company focused on transforming patient outcomes by developing rapid-acting and convenient mental health treatments. The Company's pipeline of novel therapies includes BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression (TRD), VLS-01 (DMT buccal film) for TRD and EMP-01 (oral R-MDMA) for social anxiety disorder, which are in Phase 2 clinical development. It is also advancing a drug discovery program to identify novel, non-hallucinogenic 5-HT2AR agonists for opioid use disorder and TRD. BPL-003 is being developed to produce rapid treatment effects from a single dose, within a two-hour interventional psychiatry treatment paradigm, and with a favorable safety profile. VLS-01 is a proprietary oral transmucosal film formulation of N,N-Dimethyltryptamine (DMT) being developed as a potential treatment for people living with treatment-resistant depression (TRD). EMP-01 is an oral formulation of R-MDMA.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
